Press monitoring
Sanofi: First Doses of Injectable Polio Vaccine ShanIPV(TM) Soon Available for Indian Infants
30.11.2015 | Press monitoring
Lyon, France - November 30, 2015 - Sanofi Pasteur, the vaccines division of Sanofi, announced today that the first shipment of ShanIPV (TM) , a brand new injectable, inactivated polio vaccine (IPV) manufactured by its affiliate Shantha Biotechnics, in Hyderabad, India, will occur in a couple of days. These first vaccine doses will be available to...
Medtronic Enhances Utility of Professional Continuous Glucose Monitor (CGM) by Launching Pattern Snapshot for iPro®2 Professional CGM
30.11.2015 | Press monitoring
DUBLIN - November 30, 2015 - Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced the availability of a new CareLink ® iPro report called Pattern Snapshot for iPro2 Professional CGM system. The new one-page report provides a health care professional (HCP) with information for quick interpretation of detailed glucose...
Biocartis Group NV: Biocartis announces launch of Influenza-Respiratory Virus Panel on the Idylla(TM) platform
30.11.2015 | Press monitoring
Mechelen, Belgium, 30 November 2015 - Biocartis (Euronext Brussels: BCART), an innovative molecular diagnostics company, today announces the launch of its first infectious disease test on the Idylla(TM) platform. The Idylla(TM) Respiratory IFV-RSV Panel has been developed by Janssen Diagnostics and is intended for the detection of various strains...
Climate-friendly rice recognized as a top science development of 2015
30.11.2015 | Press monitoring
The creation of a new kind of rice which gives off nearly zero greenhouse gas emissions during its growth has earned kudos for a team of scientists from three continents, including the lead investigator at the Department of Energy's Pacific Northwest National Laboratory. The new kind of rice grows in a manner that nearly eliminates the...
MPI unblinds prospective study of LungChip prognosticator in early lung cancer
27.11.2015 | Press monitoring
Hoersholm; November 27, 2015 - Medical Prognosis Institute A/S (MPI.CO) (Denmark and Phoenix, AZ, USA) announced today that the prospective LungChip study has been unblinded. LungChip is a prognostic tool for predicting which patients have a good or a bad prognosis of their lung cancer, which can have impact on treatment.
Mission space food: Sugar-growing bacteria go into orbit
27.11.2015 | Press monitoring
Matt Damon’s character in The Martian has to grow potatoes in his own faeces to survive on Mars. But there may be more appealing ways to make food in space, like using bacteria to make chemicals we can eat, such as sugar. The idea is now set to be put to the test in space for the first time. Genetically modified bacteria will be sent up on a...
ABLYNX announces nanobody drug discovery collaboration with NOVO NORDISK
25.11.2015 | Press monitoring
GHENT, Belgium, 25 November 2015 - Ablynx [Euronext Brussels: ABLX; OTC: ABYLY] today announced that it has entered into a global exclusive collaboration and licensing agreement with Novo Nordisk to discover and develop novel multi-specific Nanobody ® drug candidates for use in an undisclosed disease area, with an option to expand the agreement to...
Gene drive mosquitoes engineered to fight malaria
25.11.2015 | Press monitoring
Mutant mosquitoes engineered to resist the parasite that causes malaria could wipe out the disease in some regions – for good. Humans contract malaria from mosquitoes that are infected by parasites from the genus Plasmodium. Previous work had shown that mosquitoes could be engineered to rebuff the parasite P. falciparum, but researchers lacked a...
Sanofi and Regeneron Announce 18,000-Patient ODYSSEY OUTCOMES Trial of Praluent® (alirocumab) Injection Fully Enrolled
24.11.2015 | Press monitoring
Paris and Tarrytown, New York - November 24, 2015 - Sanofi and Regeneron Pharmaceuticals, Inc. today announced that the companies have completed enrollment in the global Phase 3 ODYSSEY OUTCOMES trial, which is prospectively evaluating the potential cardiovascular (CV) benefits of Praluent ® (alirocumab) Injection after an acute coronary syndrome...
Adaptimmune Initiates Phase I / II Trial Evaluating Its Affinity Enhanced T-Cell Therapy Targeting NY-ESO-1 in Patients With the Most Common Type of Lung Cancer
24.11.2015 | Press monitoring
OXFORD, United Kingdom and PHILADELPHIA, Nov. 24, 2015 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in the use of engineered T-cell therapy to treat cancer, today announced that it has initiated a study of its affinity enhanced T-cell therapy targeting the NY-ESO-1 cancer antigen in patients with Stage IIIb or Stage IV...
